StocksFundsScreenerSectorsWatchlists
ATRC

ATRC - AtriCure Inc Stock Price, Fair Value and News

23.39USD-0.06 (-0.26%)Market Closed

Market Summary

ATRC
USD23.39-0.06
Market Closed
-0.26%

ATRC Stock Price

View Fullscreen

ATRC RSI Chart

ATRC Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-36.57

Price/Sales (Trailing)

2.79

EV/EBITDA

-80.92

Price/Free Cashflow

-148.13

ATRC Price/Sales (Trailing)

ATRC Profitability

Operating Margin

75.23%

EBT Margin

-7.48%

Return on Equity

-6.53%

Return on Assets

-4.96%

Free Cashflow Yield

-0.68%

ATRC Fundamentals

ATRC Revenue

Revenue (TTM)

399.2M

Rev. Growth (Yr)

21.03%

Rev. Growth (Qtr)

8.4%

ATRC Earnings

Earnings (TTM)

-30.4M

Earnings Growth (Yr)

-134.75%

Earnings Growth (Qtr)

-8.11%

Breaking Down ATRC Revenue

Last 7 days

-7.6%

Last 30 days

-25.8%

Last 90 days

-30.2%

Trailing 12 Months

-44.4%

How does ATRC drawdown profile look like?

ATRC Financial Health

Current Ratio

3.57

Debt/Equity

0.13

Debt/Cashflow

0.07

ATRC Investor Care

Shares Dilution (1Y)

2.20%

Diluted EPS (TTM)

-0.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023349.3M365.7M380.7M399.2M
2022289.6M302.8M315.6M330.4M
2021212.6M243.1M258.8M274.3M
2020230.1M212.0M210.1M206.5M
2019208.6M215.7M222.4M230.8M
2018180.4M187.0M194.8M201.6M
2017160.4M166.0M169.8M174.7M
2016135.8M142.9M149.8M155.1M
2015112.5M118.6M123.3M129.8M
201487.3M93.4M99.9M107.5M
201372.2M74.4M78.4M81.9M
201266.2M67.7M68.6M70.2M
201160.7M63.3M64.0M64.4M
2010056.0M57.5M59.0M
200900054.5M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of AtriCure Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 01, 2024
noznesky justin j
sold
-45,585
30.39
-1,500
chief mktg & strategy officer
Mar 18, 2024
dahlquist karl s.
sold
-60,621
32.16
-1,885
chief legal officer
Mar 14, 2024
carrel michael h
gifted
-
-
-2,000
president, ceo, & director
Mar 12, 2024
noznesky justin j
sold
-55,080
36.72
-1,500
chief mktg & strategy officer
Mar 05, 2024
dahlquist karl s.
sold
-307,510
37.36
-8,231
chief legal officer
Mar 01, 2024
yount deborah lee
sold (taxes)
-
-
-2,056
chief human resources officer
Mar 01, 2024
seith douglas j
sold (taxes)
-529,543
36.28
-14,596
chief operating officer
Mar 01, 2024
noznesky justin j
acquired
-
-
28,622
chief mktg & strategy officer
Mar 01, 2024
privitera salvatore
acquired
-
-
26,427
chief technical officer
Mar 01, 2024
carrel michael h
sold (taxes)
-1,735,050
36.28
-47,824
president, ceo, & director

1–10 of 50

Which funds bought or sold ATRC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 15, 2024
WEST PACES ADVISORS INC.
unchanged
-
-131
761
-%
Apr 09, 2024
MASSMUTUAL TRUST CO FSB/ADV
sold off
-100
-357
-
-%
Apr 09, 2024
MATHER GROUP, LLC.
new
-
5,889
5,889
-%
Apr 05, 2024
LOS ANGELES CAPITAL MANAGEMENT LLC
new
-
842,421
842,421
-%
Apr 05, 2024
CWM, LLC
reduced
-41.77
-3,000
3,000
-%
Apr 03, 2024
Versant Capital Management, Inc
new
-
213
213
-%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
added
2.25
-43,882
219,137
-%
Mar 21, 2024
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
new
-
2,028,940
2,028,940
0.01%
Mar 11, 2024
VANGUARD GROUP INC
added
1.62
-35,317,300
170,100,000
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
193
14,780,700
25,382,800
-%

1–10 of 47

Are Funds Buying or Selling ATRC?

Are funds buying ATRC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ATRC
No. of Funds

Unveiling AtriCure Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
alliancebernstein l.p.
7.2%
3,394,036
SC 13G/A
Feb 13, 2024
vanguard group inc
10.06%
4,766,029
SC 13G/A
Feb 01, 2024
invesco ltd.
2.5%
1,162,050
SC 13G/A
Jan 25, 2024
blackrock inc.
8.8%
4,193,887
SC 13G/A
Dec 08, 2023
vanguard group inc
10.01%
4,745,971
SC 13G/A
Feb 14, 2023
alliancebernstein l.p.
7.7%
3,565,726
SC 13G/A
Feb 14, 2023
alger associates inc
3.8%
1,755,398
SC 13G/A
Feb 09, 2023
vanguard group inc
9.44%
4,389,815
SC 13G/A
Feb 03, 2023
blackrock inc.
8.0%
3,735,766
SC 13G/A
Feb 03, 2023
invesco ltd.
7.2%
3,367,324
SC 13G/A

Recent SEC filings of AtriCure Inc

View All Filings
Date Filed Form Type Document
Apr 03, 2024
4
Insider Trading
Apr 03, 2024
DEF 14A
DEF 14A
Apr 03, 2024
DEFA14A
DEFA14A
Apr 01, 2024
144
Notice of Insider Sale Intent
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
PRE 14A
PRE 14A
Mar 18, 2024
144
Notice of Insider Sale Intent
Mar 18, 2024
4
Insider Trading
Mar 14, 2024
4
Insider Trading
Mar 12, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to AtriCure Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
182.6B
40.1B
-6.98% -6.26%
31.91
4.55
-8.12% -17.45%
67.4B
19.5B
-2.95% -9.93%
53.63
3.46
4.02% -22.04%
22.6B
3.9B
-4.96% -15.40%
50.88
5.86
3.42% 23.09%
20.1B
14.8B
-5.44% -9.06%
7.58
1.36
2.12% 209.17%
MID-CAP
9.2B
3.5B
-0.25% 17.23%
32.28
2.63
4.97% 18.89%
9.0B
12.3B
-5.97% -15.68%
21.61
0.73
-2.44% -22.68%
8.2B
2.7B
-16.50% -42.23%
-12.88
3.07
-4.68% 82.43%
6.3B
4.0B
-8.09% -25.03%
-46.91
1.59
1.10% 85.84%
3.4B
366.4M
-2.40% 13.34%
-563.48
9.33
33.86% 89.83%
2.3B
6.6B
-5.10% -3.56%
11.79
0.35
2.78% -0.87%
SMALL-CAP
1.2B
3.2B
-10.67% -21.18%
-1.84
0.39
7.73% -1066.14%
377.6M
166.7M
0.43% -6.80%
-4.57
2.27
6.67% -456.34%
245.1M
324.0M
10.27% -31.54%
-1.27
0.76
-3.19% -337.41%
47.8M
52.3M
-23.89% -53.56%
-2.55
0.91
17.61% 19.28%
3.7M
3.7M
-12.80% 240.48%
-0.3
0.99
5.77% 8.23%

AtriCure Inc News

Latest updates
Yahoo Movies Canada20 hours ago
Defense World17 Apr 202409:03 am
MarketBeat02 Apr 202404:53 pm
Yahoo Finance22 Mar 202407:00 am
Simply Wall St14 Mar 202407:00 am
Yahoo Finance27 Feb 202408:00 am

AtriCure Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue8.4%106,543,00098,290,000100,918,00093,494,00088,028,00083,246,00084,529,00074,576,00073,218,00070,460,00071,376,00059,275,00057,725,00054,757,00040,824,00053,225,00061,321,00056,614,00058,906,00053,966,00052,893,000
Cost Of Revenue9.4%26,728,00024,421,00023,841,00023,885,00022,915,00021,533,00021,010,00018,981,00018,202,00018,234,00017,298,00014,735,00015,288,00014,423,00013,170,00014,341,00016,547,00014,817,00015,013,00014,095,00014,303,000
Gross Profit8.0%79,815,00073,869,00077,077,00069,609,00065,113,00061,713,00063,519,00055,595,00055,016,00052,226,00054,078,00044,540,00042,437,00040,334,00027,654,00038,884,00044,774,00041,797,00043,893,00039,871,00038,590,000
Operating Expenses8.0%88,483,00081,958,00081,221,00075,391,00069,249,00072,436,00077,179,00069,745,00067,518,000-46,443,00069,155,00060,425,00059,940,00044,325,00034,939,00054,338,00060,100,00050,434,00047,732,00045,191,00041,197,000
  S&GA Expenses9.9%67,687,00061,604,00063,783,00060,064,00055,501,00057,267,00062,388,00056,116,00051,160,00049,873,00056,958,00049,208,00047,095,00033,557,00024,903,00042,751,00051,920,00040,280,00037,928,00037,015,00032,742,000
  R&D Expenses2.2%20,796,00020,354,00017,438,00015,327,00013,748,00015,169,00014,791,00013,629,00013,808,00011,284,00012,197,00011,217,00010,871,00010,576,00010,036,00011,587,00013,096,00010,154,0009,804,0008,176,0008,455,000
EBITDA Margin-48.7%-0.03-0.02-0.03-0.07-0.10-0.140.220.220.230.23-0.18-0.17---------
Interest Expenses1.5%1,798,0001,772,0001,719,0001,636,0001,561,0001,324,0001,101,0001,000,0001,083,0001,449,0001,197,0001,189,0001,194,0001,232,0001,231,0001,228,0001,257,0001,113,000879,000862,0001,320,000
Income Taxes693.6%373,00047,00093,00078,000121,00046,00045,00056,00053,00038,00066,00031,00098,000-4,00012,0008,00048,00075,00010,00066,00079,000
Earnings Before Taxes-4.5%-9,416,000-9,008,000-5,025,000-6,398,000-4,049,000-12,226,000-14,796,000-15,127,000-13,688,00097,146,000-16,185,000-16,886,000-18,464,000-4,953,000-8,224,000-16,400,000-16,048,000-9,287,000-4,091,000-5,569,000-3,351,000
EBT Margin-16.3%-0.07-0.06-0.08-0.11-0.14-0.180.180.180.180.18-0.23-0.23---------
Net Income-8.1%-9,789,000-9,055,000-5,118,000-6,476,000-4,170,000-12,272,000-14,841,000-15,183,000-13,741,00097,108,000-16,251,000-16,917,000-18,562,000-4,949,000-8,236,000-16,408,000-16,096,000-9,362,000-4,101,000-5,635,000-3,430,000
Net Income Margin-17.0%-0.08-0.07-0.08-0.11-0.14-0.180.180.180.180.18-0.23-0.23---------
Free Cashflow159.0%1,244,000-2,108,000-69,000-6,581,000-4,125,000-6,929,00045,000-28,013,000-2,409,000-1,736,000-8,746,000-10,642,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets2.3%614600594583585582587585615613701700715708704528558561343338357
  Current Assets5.4%266253238238215212206200196196236298307296292127143138147155175
    Cash Equivalents4.6%84.0081.0067.0077.0058.0049.0055.0028.0044.0040.0068.0085.0042.0033.0089.0022.0028.0033.0025.0021.0032.00
  Inventory9.7%68.0062.0055.0049.0046.0044.0041.0041.0039.0039.0038.0036.0035.0034.0033.0032.0029.0028.0024.0024.0022.00
  Net PPE------39.0036.0033.0031.0030.0030.0028.0028.0029.0030.0032.0033.0031.0028.0027.0027.00
  Goodwill0%235235235235235235235235235235235235235235235235235236105105105
Liabilities7.5%14813713212812913213112213212531630930229028730031130310299.00107
  Current Liabilities-9.7%75.0083.0071.0062.0058.0058.0056.0047.0056.0054.0067.0058.0049.0045.0038.0039.0050.0044.0039.0035.0040.00
  Long Term Debt43.7%61.0042.0047.0052.0057.0060.0060.0060.0060.0056.0044.0049.0053.0050.0054.0058.0060.0060.0034.0033.0036.00
    LT Debt, Non Current43.7%61.0042.0047.0052.0057.0060.0060.0060.0060.0056.0044.0049.0053.0050.0054.0058.0060.0060.0034.0033.0036.00
Shareholder's Equity0.7%466463462455457450457463484488385391412418417227247258242239249
  Retained Earnings-2.8%-357-347-338-333-326-322-310-295-280-266-363-347-330-311-306-298-282-266-256-252-247
  Additional Paid-In Capital1.5%824812803791787778771762765755749738742729724526530525498492497
Shares Outstanding0.3%48.0047.0047.0047.0047.0046.0046.0046.0045.0045.0045.0045.00---------
Float---2,276---1,852---3,556---1,961---1,111--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations164.8%4,0301,5223,011-4,07946.00-1,7844,229-24,632301-232-4,533-9,3163,9543,812-11,548-16,087-3,529-2,5903,746-13,438985
  Share Based Compensation7.5%9,3128,6618,9958,7607,1977,0017,5247,0497,5396,7947,1416,6046,5165,5496,1934,3845,1614,2874,3754,1544,829
Cashflow From Investing-123.5%-2,78611,870-16,08028,8137,002-3,23920,52119,7221,077-25,101-16,05963,587-1,980-58,737-112,81217,331-2,601-9,633-93011,017-70,826
Cashflow From Financing1687.1%2,3591322,994-5,5171,982-4051,861-10,4972,507-2,2602,818-10,7076,453-301191,074-7,8341,35420,2931,696-8,97084,129

ATRC Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Revenue$ 399,245$ 330,379$ 274,329
Cost of revenue98,87584,43968,469
Gross profit300,370245,940205,860
Operating expenses (benefit):   
Research and development expenses73,91557,33748,506
Selling, general and administrative expenses253,138231,272204,649
Change in fair value of contingent consideration (Note 2)00(184,800)
Intangible asset impairment (Note 4)0082,300
Total operating expenses327,053288,609150,655
(Loss) income from operations(26,683)(42,669)55,205
Other income (expense):   
Interest expense(6,925)(4,986)(4,918)
Interest income3,7921,994466
Other(31)(537)(366)
(Loss) income before income tax expense(29,847)(46,198)50,387
Income tax expense591268188
Net (loss) income$ (30,438)$ (46,466)$ 50,199
Net (loss) income per share:   
Basic net (loss) income per share (in usd per share)$ (0.66)$ (1.02)$ 1.11
Diluted net (loss) income per share (in usd per share)$ (0.66)$ (1.02)$ 1.09
Weighted average shares outstanding:   
Weighted average shares outstanding, basic (in shares)46,30945,74045,066
Weighted average shares outstanding, diluted (in shares)46,30945,74046,039
Comprehensive (loss) income:   
Unrealized gain (loss) on investments$ 2,898$ (2,811)$ (941)
Foreign currency translation adjustment205(337)(319)
Other comprehensive income (loss)3,103(3,148)(1,260)
Net (loss) income(30,438)(46,466)50,199
Comprehensive (loss) income, net of tax$ (27,335)$ (49,614)$ 48,939

ATRC Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 84,310$ 58,099
Short-term investments52,97563,014
Accounts receivable, less allowance for credit losses of $500 and $23052,50142,693
Inventories67,89745,931
Prepaid and other current assets8,5635,477
Total current assets266,246215,214
Assets, Noncurrent  
Long-term investments051,509
Property and equipment, net42,43538,833
Operating lease right-of-use assets4,3243,787
Intangible assets, net63,98639,339
Goodwill234,781234,781
Other noncurrent assets2,1601,985
Total Assets613,932585,448
Current liabilities:  
Accounts payable27,35419,898
Accrued liabilities44,68233,022
Current maturities of debt and leases2,5335,472
Total current liabilities74,56958,392
Long-term debt60,59356,834
Finance lease liabilities8,0619,147
Operating lease liabilities3,3073,095
Other noncurrent liabilities1,2341,226
Total Liabilities147,764128,694
Commitments and contingencies (Note 10)
Stockholders’ Equity:  
Common stock, $0.001 par value, 90,000 shares authorized; 47,526 and 46,563 issued and outstanding4847
Additional paid-in capital824,170787,422
Accumulated other comprehensive loss(993)(4,096)
Accumulated deficit(357,057)(326,619)
Total Stockholders’ Equity466,168456,754
Total Liabilities and Stockholders’ Equity$ 613,932$ 585,448
ATRC
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
 CEO
 WEBSITEatricure.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES1050

AtriCure Inc Frequently Asked Questions


What is the ticker symbol for AtriCure Inc? What does ATRC stand for in stocks?

ATRC is the stock ticker symbol of AtriCure Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AtriCure Inc (ATRC)?

As of Thu Apr 18 2024, market cap of AtriCure Inc is 1.11 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATRC stock?

You can check ATRC's fair value in chart for subscribers.

What is the fair value of ATRC stock?

You can check ATRC's fair value in chart for subscribers. The fair value of AtriCure Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AtriCure Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATRC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AtriCure Inc a good stock to buy?

The fair value guage provides a quick view whether ATRC is over valued or under valued. Whether AtriCure Inc is cheap or expensive depends on the assumptions which impact AtriCure Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATRC.

What is AtriCure Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, ATRC's PE ratio (Price to Earnings) is -36.57 and Price to Sales (PS) ratio is 2.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATRC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AtriCure Inc's stock?

In the past 10 years, AtriCure Inc has provided 0.036 (multiply by 100 for percentage) rate of return.